Cover Image

A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors

A drug interaction is a condition in which two or more drugs are taken at the same time. Type 2 diabetes mellitus is a significant contributor to polypharmacy. Proton pump inhibitors (PPIs) are often prescribed in combination with metformin or DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin,...

Full description

Saved in:
Bibliographic Details
Main Authors: Tasnim, Jarin, Hashim, Najihah Mohd, Han, Heh Choon
Format: Article
Published: Wiley 2024
Subjects:
RM Therapeutics. Pharmacology
RS Pharmacy and materia medica
Online Access:http://eprints.um.edu.my/47037/
https://doi.org/10.1002/cbf.3967
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.47037
record_format eprints
spelling my.um.eprints.470372025-01-06T04:31:59Z http://eprints.um.edu.my/47037/ A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors Tasnim, Jarin Hashim, Najihah Mohd Han, Heh Choon RM Therapeutics. Pharmacology RS Pharmacy and materia medica A drug interaction is a condition in which two or more drugs are taken at the same time. Type 2 diabetes mellitus is a significant contributor to polypharmacy. Proton pump inhibitors (PPIs) are often prescribed in combination with metformin or DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) or a combined dose of metformin and DPP-4 inhibitor to treat gastritis in diabetic patients. This review article mainly focused on evaluating the potential drug-drug interactions (DDIs) between PPIs (i.e. esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) with metformin and PPIs with DPP-4 inhibitors. The findings demonstrated the existence of pharmacokinetic and pharmacodynamic DDIs between the aforementioned PPIs with metformin and DPP-4 inhibitors, which could impact the biological activities (i.e., hypoglycemia) of these drugs. Moreover, this review suggested that esomeprazole could be the best drug in the PPI group to be prescribed simultaneously with metformin and DPP-4 inhibitors, as most of the antidiabetic drugs of this study did not show any interaction with esomeprazole. The findings of this study also revealed that both antidiabetic drugs and PPIs could have positive interactions as PPIs have the potential to lessen the gastrointestinal side effects of metformin and DPP-4 inhibitors. To achieve the greatest therapeutic impact with the fewest side effects, careful dose control of these drugs is required. So, more extensive research on both human and animal subjects are needed to ascertain the veracity of this hypothesis. This review highlights that metformin and DPP-4 inhibitors often cause gastrointestinal side effects, leading to the coadministration of proton pump inhibitors (PPIs). It systematically explores potential drug-drug interactions of PPIs with metformin and DPP-4 inhibitors, revealing impacts on absorption, metabolism, and antidiabetic activity. The paper emphasizes the need for careful dose control when prescribing these drugs concurrently, aiming for optimal therapeutic impact with minimal side effects. With a lack of prior research on this topic, the article suggests a potential avenue for extensive in vitro, in vivo, and human studies to confirm the drug interactions, providing valuable insights for drug prescribers and researchers in diabetes management. Wiley 2024-03 Article PeerReviewed Tasnim, Jarin and Hashim, Najihah Mohd and Han, Heh Choon (2024) A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors. Cell Biochemistry and Function, 42 (2). e3967. ISSN 0263-6484, DOI https://doi.org/10.1002/cbf.3967 <https://doi.org/10.1002/cbf.3967>. https://doi.org/10.1002/cbf.3967 10.1002/cbf.3967
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic RM Therapeutics. Pharmacology
RS Pharmacy and materia medica
spellingShingle RM Therapeutics. Pharmacology
RS Pharmacy and materia medica
Tasnim, Jarin
Hashim, Najihah Mohd
Han, Heh Choon
A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors
description A drug interaction is a condition in which two or more drugs are taken at the same time. Type 2 diabetes mellitus is a significant contributor to polypharmacy. Proton pump inhibitors (PPIs) are often prescribed in combination with metformin or DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) or a combined dose of metformin and DPP-4 inhibitor to treat gastritis in diabetic patients. This review article mainly focused on evaluating the potential drug-drug interactions (DDIs) between PPIs (i.e. esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) with metformin and PPIs with DPP-4 inhibitors. The findings demonstrated the existence of pharmacokinetic and pharmacodynamic DDIs between the aforementioned PPIs with metformin and DPP-4 inhibitors, which could impact the biological activities (i.e., hypoglycemia) of these drugs. Moreover, this review suggested that esomeprazole could be the best drug in the PPI group to be prescribed simultaneously with metformin and DPP-4 inhibitors, as most of the antidiabetic drugs of this study did not show any interaction with esomeprazole. The findings of this study also revealed that both antidiabetic drugs and PPIs could have positive interactions as PPIs have the potential to lessen the gastrointestinal side effects of metformin and DPP-4 inhibitors. To achieve the greatest therapeutic impact with the fewest side effects, careful dose control of these drugs is required. So, more extensive research on both human and animal subjects are needed to ascertain the veracity of this hypothesis. This review highlights that metformin and DPP-4 inhibitors often cause gastrointestinal side effects, leading to the coadministration of proton pump inhibitors (PPIs). It systematically explores potential drug-drug interactions of PPIs with metformin and DPP-4 inhibitors, revealing impacts on absorption, metabolism, and antidiabetic activity. The paper emphasizes the need for careful dose control when prescribing these drugs concurrently, aiming for optimal therapeutic impact with minimal side effects. With a lack of prior research on this topic, the article suggests a potential avenue for extensive in vitro, in vivo, and human studies to confirm the drug interactions, providing valuable insights for drug prescribers and researchers in diabetes management.
format Article
author Tasnim, Jarin
Hashim, Najihah Mohd
Han, Heh Choon
author_facet Tasnim, Jarin
Hashim, Najihah Mohd
Han, Heh Choon
author_sort Tasnim, Jarin
title A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors
title_short A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors
title_full A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors
title_fullStr A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors
title_full_unstemmed A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors
title_sort comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and dpp-4 inhibitors
publisher Wiley
publishDate 2024
url http://eprints.um.edu.my/47037/
https://doi.org/10.1002/cbf.3967
_version_ 1821105757359177728
score 13.239859

Similar Items